Antimicrobial peptides and methods of use thereof
AssigneeThe Board of Regents of the University of Oklahoma
InventorH. Anne Pereira
Life of this patent
Estimating the term…
Abstract
Novel peptide analogs derived from the native sequences of CAP37 peptides 20-44 and 23-42, and their use as therapeutics against bacterial infections and diseases caused by bacterial infection. The peptide analog includes a serine or threonine substitution at one of the two cysteine residues at positions 26 and 42. Substitutions of the native peptide are also contemplated.
Claims6
A method of treating a bacterial infection in a subject, comprising:
- administering a therapeutically effective amount of a peptide comprising a derivative of CAP37 peptide 23-42 (cationic antimicrobial protein of molecular weight 37 kDa) (SEQ ID NO:2) wherein one of the cysteine residues at positions 26 and 42 is substituted with a serine or threonine residue and one of the cysteine residues at positions 26 and 42 is left unsubstituted.
A method of treating septic shock in a subject or prophylactically preventing septic shock in a subject, comprising:
- administering a therapeutically effective amount of a peptide comprising a derivative of CAP37 peptide 23-42 (cationic antimicrobial protein of molecular weight 37 kDa) (SEQ ID NO:2) wherein one of the cysteine residues at positions 26 and 42 is substituted with a serine or threonine residue and one of the cysteine residues at positions 26 and 42 is left unsubstituted.
A method of treating a bacterial infection in a subject, comprising:
- administering a therapeutically effective amount of a peptide having the sequence:
- R-H-X1-X2-X3-X4-X5-X6-X7-H-X8-R-X9-X10-M-X11-X12-X13-X14-X15
- wherein:
- X1 is phe or tyr;
- X2 is cys, ser, or thr;
- X3 is gly or ala;
- X4 is gly or ala;
- X5-X8, X10, X12 and X13 are ala, leu, ile or val;
- X9 is phe or tyr;
- X11 is ser or thr;
- X14 is ser, thr, his, arg or lys;
- X15 is ser, cys or thr;
- R is arg;
- H is his;
- and
- M is met;
- and with the proviso that when X2 is cys, X15 is ser or thr and when X15 is cys, X2 is ser or thr.
A therapeutic composition, comprising:
- a pharmaceutically acceptable carrier;
- and
- a peptide comprising the amino acid sequence:
- R-H-X1-X2-X3-X4-X5-X6-X7-H-X8-R-X9-X10-M-X11-X12-X13-X14-X15
- wherein:
- X1 is phe or tyr;
- X2 is cys, ser, or thr;
- X3 is gly or ala;
- X4 is gly or ala;
- X5-X8, X10, X12 and X13 are ala, leu, ile or val;
- X9 is phe or tyr;
- X11 is ser or thr;
- X14 is ser, thr, his, arg or lys;
- X15 is ser, cys or thr;
- R is arg;
- H is his;
- and
- M is met;
- and with the proviso that when X2 is cys, X15 is ser or thr and when X15 is cys, X2 is ser or thr.
Dependencies are inferred from the claim text.